D. H. Taylor, Author at Smarter Analyst

Investment Newsletters

About the Author D. H. Taylor

I am an economist and mathematician having studied at the University of Denver. I trade my own account. I eat what I kill. I focus on the consumer and the economics of that consumer. I start my focus on the consumer and look at economic data to determine how strong the consumer is at any moment. From that, I extrapolate the state of the consumer and shopping trends at retailers as well as purchasing of housing and autos. I follow the major trends of these to determine the health of the economy here in America and abroad. Being from California and Colorado, I am all-too familiar with cannabis. I am actively building a portfolio of cannabis biopharmaceuticals for my private investment. Also, I evaluate the cannabis stocks on a whole.

Acreage Holdings’ (ACRGF) Strong Board Presence Can Push the Stock Higher

When you start to research Acreage Holdings (ACRGF), one of the biggest cannabis companies in the US, there is one thing about the …

D. H. Taylor — February 28, 2019, 3:03 PM EDT

A Growing Medical Cannabis Stock That Flies Under the Radar

I am an ardent adherent to the benefits of cannabis, specifically CBD, the compound in cannabis that provides the health benefits that are …

D. H. Taylor — February 28, 2019, 1:12 PM EDT

Analyst Sees This Cannabis Stock More Than Doubling

Jefferies sees The Green Organic Dutchman (TGODF) stock doubling in the value of the course of the next year with potential to go …

D. H. Taylor — February 27, 2019, 11:22 AM EDT

Has Cronos (CRON) Stock Gone Too Far?

Wall Street investment firm Jefferies believes that post-Altria (MO) deal Cronos (CRON) stock has gotten ahead of itself. Jefferies analyst Owen Bennett has initiated …

D. H. Taylor — February 27, 2019, 10:20 AM EDT

This Medical Cannabis Player Has Big Ambitions, But Will It Succeed?

$3.5 billion Curaleaf (CURLF) came on the scene via a merge of two separate companies.

D. H. Taylor — February 26, 2019, 2:46 PM EDT

GW Pharma (GWPH) Stock Could Surge on Earnings Today

GW Pharma (GWPH) has the distinction of having the first cannabis-derived prescription drug that was approved by the FDA: Epidiolex. This drug is …

D. H. Taylor — February 26, 2019, 1:33 PM EDT

These 3 Tiny Pot Stocks Are Diamonds in the Rough

Industry participants believe the cannabis segment will become a $500 billion industry. For now, it is a fraction of that potential.

D. H. Taylor — February 26, 2019, 1:12 PM EDT

How Risky Is This Marijuana Stock?

After a string of what some considered successes, MedMen Enterprises (MMNFF) is facing self-made adversity. The CFO of the company left MedMen about …

D. H. Taylor — February 25, 2019, 10:42 AM EDT

CannTrust (CTST): An Undervalued Pot Stock Just Got Listed on the Big Board

Liquidity is often a key factor in how a stock will be priced. Often times, if there is not enough liquidity, a stock …

D. H. Taylor — February 25, 2019, 10:03 AM EDT

Why Canopy Growth (CGC) Stock Has What It Takes

I am a numbers person and am always pouring through data. The numbers I keep coming up with are that Canada is always …

D. H. Taylor — February 25, 2019, 9:33 AM EDT

1 2 »